Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Carbavance (meropenem/RPX7009) vs piperacillin + tazobactam in complicated urinary tract infection and acute pyelonephritis
2014-000545-78Phase 3Completed
- Sponsor
- Rempex Pharmaceuticals, Inc.
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of meropenem + vaborbactam in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Rempex Pharmaceuticals, Inc. Primary endpoint: Primary Endpoint for EMA. Started Sep 2014; status: completed.
02
Drugs
meropenem + vaborbactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2014-000545-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000545-78.